vs
Side-by-side financial comparison of GAIA, INC (GAIA) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
GAIA, INC is the larger business by last-quarter revenue ($25.5M vs $18.6M, roughly 1.4× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -0.3%, a 66.0% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 5.8%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 9.4%).
Gaia, Inc. is a publicly traded (NASDAQ:GAIA) American media company founded in 1988 by Jirka Rysavy in Louisville, Colorado. It owns and operates Gaia TV, a subscription video on-demand service consisting of original and licensed alternative media documentaries, including those on wellness, spirituality and conspiracy theories.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
GAIA vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.5M | $18.6M |
| Net Profit | $-75.0K | $12.3M |
| Gross Margin | 87.6% | — |
| Operating Margin | -2.6% | 56.3% |
| Net Margin | -0.3% | 65.7% |
| Revenue YoY | 5.8% | 1808.5% |
| Net Profit YoY | 91.7% | 376.5% |
| EPS (diluted) | $-0.02 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.5M | $18.6M | ||
| Q3 25 | $25.0M | $334.0K | ||
| Q2 25 | $24.6M | $1.4M | ||
| Q1 25 | $23.8M | $257.0K | ||
| Q4 24 | $24.1M | $977.0K | ||
| Q3 24 | $22.0M | $660.0K | ||
| Q2 24 | $21.9M | $736.0K | ||
| Q1 24 | $21.3M | $1.4M |
| Q4 25 | $-75.0K | $12.3M | ||
| Q3 25 | $-1.2M | $-8.6M | ||
| Q2 25 | $-2.0M | $-6.9M | ||
| Q1 25 | $-1.2M | $-5.4M | ||
| Q4 24 | $-907.0K | — | ||
| Q3 24 | $-1.2M | $-2.8M | ||
| Q2 24 | $-2.2M | $-14.5M | ||
| Q1 24 | $-971.0K | $411.0K |
| Q4 25 | 87.6% | — | ||
| Q3 25 | 86.4% | — | ||
| Q2 25 | 86.7% | — | ||
| Q1 25 | 87.7% | — | ||
| Q4 24 | 88.2% | — | ||
| Q3 24 | 86.1% | — | ||
| Q2 24 | 84.5% | — | ||
| Q1 24 | 85.3% | — |
| Q4 25 | -2.6% | 56.3% | ||
| Q3 25 | -5.0% | -2516.5% | ||
| Q2 25 | -8.9% | -701.0% | ||
| Q1 25 | -4.3% | -3350.2% | ||
| Q4 24 | -7.1% | — | ||
| Q3 24 | -5.3% | -1563.6% | ||
| Q2 24 | -9.1% | -1255.0% | ||
| Q1 24 | -4.0% | -692.5% |
| Q4 25 | -0.3% | 65.7% | ||
| Q3 25 | -4.6% | -2572.2% | ||
| Q2 25 | -8.3% | -504.8% | ||
| Q1 25 | -5.1% | -2097.7% | ||
| Q4 24 | -3.8% | — | ||
| Q3 24 | -5.4% | -425.5% | ||
| Q2 24 | -9.9% | -1964.4% | ||
| Q1 24 | -4.6% | 29.9% |
| Q4 25 | $-0.02 | $0.25 | ||
| Q3 25 | $-0.05 | $-0.17 | ||
| Q2 25 | $-0.07 | $-0.14 | ||
| Q1 25 | $-0.04 | $-0.11 | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $-0.05 | $-0.06 | ||
| Q2 24 | $-0.09 | $-0.30 | ||
| Q1 24 | $-0.05 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $87.9M | $49.4M |
| Total Assets | $154.6M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | $40.0M | ||
| Q3 25 | $14.2M | $37.9M | ||
| Q2 25 | $13.9M | $44.8M | ||
| Q1 25 | $13.1M | $40.6M | ||
| Q4 24 | $5.9M | $59.3M | ||
| Q3 24 | $4.4M | $68.8M | ||
| Q2 24 | $5.5M | $73.0M | ||
| Q1 24 | $8.6M | $80.2M |
| Q4 25 | $87.9M | $49.4M | ||
| Q3 25 | $86.3M | $36.4M | ||
| Q2 25 | $85.7M | $44.5M | ||
| Q1 25 | $87.0M | $50.5M | ||
| Q4 24 | $80.7M | $55.1M | ||
| Q3 24 | $81.2M | $58.5M | ||
| Q2 24 | $82.1M | $60.4M | ||
| Q1 24 | $84.8M | $74.1M |
| Q4 25 | $154.6M | $59.0M | ||
| Q3 25 | $151.1M | $51.1M | ||
| Q2 25 | $147.0M | $60.7M | ||
| Q1 25 | $148.5M | $67.9M | ||
| Q4 24 | $141.2M | $90.6M | ||
| Q3 24 | $139.6M | $99.0M | ||
| Q2 24 | $142.1M | $107.8M | ||
| Q1 24 | $133.8M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $18.4M |
| Free Cash FlowOCF − Capex | $76.0K | — |
| FCF MarginFCF / Revenue | 0.3% | — |
| Capex IntensityCapex / Revenue | 6.6% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-377.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $18.4M | ||
| Q3 25 | $326.0K | $-8.7M | ||
| Q2 25 | $2.3M | $-7.5M | ||
| Q1 25 | $1.3M | $-7.5M | ||
| Q4 24 | $2.7M | $-24.0M | ||
| Q3 24 | $409.0K | $765.0K | ||
| Q2 24 | $-2.1M | $-10.9M | ||
| Q1 24 | $5.9M | $-4.0M |
| Q4 25 | $76.0K | — | ||
| Q3 25 | $-1.6M | — | ||
| Q2 25 | $880.0K | — | ||
| Q1 25 | $268.0K | — | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $-952.0K | — | ||
| Q2 24 | $-3.5M | — | ||
| Q1 24 | $4.9M | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | -6.4% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 6.5% | — | ||
| Q3 24 | -4.3% | — | ||
| Q2 24 | -16.1% | — | ||
| Q1 24 | 22.8% | — |
| Q4 25 | 6.6% | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | 5.7% | — | ||
| Q1 25 | 4.3% | — | ||
| Q4 24 | 4.6% | — | ||
| Q3 24 | 6.2% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 5.0% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GAIA
| US | $16.7M | 65% |
| Non Us | $8.8M | 35% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
